Myrthala Moreno-Smith
Overview
Explore the profile of Myrthala Moreno-Smith including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
891
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Allen J, Armaiz-Pena G, Nagaraja A, Sadaoui N, Ortiz T, Dood R, et al.
Cancer Res
. 2018 Apr;
78(12):3233-3242.
PMID: 29661830
Mounting clinical and preclinical evidence supports a key role for sustained adrenergic signaling in the tumor microenvironment as a driver of tumor growth and progression. However, the mechanisms by which...
12.
Van Goethem A, Yigit N, Moreno-Smith M, Vasudevan S, Barbieri E, Speleman F, et al.
Oncotarget
. 2017 Sep;
8(34):57047-57057.
PMID: 28915653
Wild-type p53 tumor suppressor activity in neuroblastoma tumors is hampered by increased MDM2 activity, making selective MDM2 antagonists an attractive therapeutic strategy for this childhood malignancy. Since monotherapy in cancer...
13.
Moreno-Smith M, Lakoma A, Chen Z, Tao L, Scorsone K, Schild L, et al.
Clin Cancer Res
. 2017 Aug;
23(21):6629-6639.
PMID: 28821555
mTORC1 inhibitors are promising agents for neuroblastoma therapy; however, they have shown limited clinical activity as monotherapy, thus rational drug combinations need to be explored to improve efficacy. Importantly, neuroblastoma...
14.
Van Goethem A, Yigit N, Everaert C, Moreno-Smith M, Mus L, Barbieri E, et al.
Sci Rep
. 2016 Dec;
6:37876.
PMID: 27901112
The ongoing ascent of sequencing technologies has enabled researchers to gain unprecedented insights into the RNA content of biological samples. MiRNAs, a class of small non-coding RNAs, play a pivotal...
15.
Pecot C, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, et al.
Nat Commun
. 2013 Sep;
4:2427.
PMID: 24018975
The miR-200 family is well known to inhibit the epithelial-mesenchymal transition, suggesting it may therapeutically inhibit metastatic biology. However, conflicting reports regarding the role of miR-200 in suppressing or promoting...
16.
Moreno-Smith M, Lee S, Lu C, Nagaraja A, He G, Rupaimoole R, et al.
Neoplasia
. 2013 May;
15(5):502-10.
PMID: 23633922
Chronic sympathetic nervous system activation results in increased angiogenesis and tumor growth in orthotopic mouse models of ovarian carcinoma. However, the mechanistic effects of such activation on the tumor vasculature...
17.
Moreno-Smith M, Halder J, Meltzer P, Gonda T, Mangala L, Rupaimoole R, et al.
J Clin Invest
. 2013 Apr;
123(5):2119-30.
PMID: 23585472
Platinum compounds display clinical activity against a wide variety of solid tumors; however, resistance to these agents is a major limitation in cancer therapy. Reduced platinum uptake and increased platinum...
18.
Moreno-Smith M, Lu C, Shahzad M, Pena G, Allen J, Stone R, et al.
Clin Cancer Res
. 2011 May;
17(11):3649-59.
PMID: 21531818
Purpose: Increased adrenergic activity in response to chronic stress is known to promote tumor growth by stimulating the tumor microenvironment. The focus of the current study was to determine whether...
19.
Moreno-Smith M, Lutgendorf S, Sood A
Future Oncol
. 2010 Dec;
6(12):1863-81.
PMID: 21142861
The influence of psychosocial factors on the development and progression of cancer has been a longstanding hypothesis since ancient times. In fact, epidemiological and clinical studies over the past 30...
20.
Shahzad M, Arevalo J, Armaiz-Pena G, Lu C, Stone R, Moreno-Smith M, et al.
J Biol Chem
. 2010 Sep;
285(46):35462-70.
PMID: 20826776
A growing number of studies indicate that chronic stress can accelerate tumor growth due to sustained sympathetic nervous system activation. Our recent findings suggest that chronic stress is associated with...